Article Cited by others


Pharmacovigilance in Asia

Biswas Pipasha

Year : 2013| Volume: 4| Issue : 5 | Page no: 7-19

   This article has been cited by
1 Pharmacovigilance in China: development and challenges
Ying Zhao,Tiansheng Wang,Guangyao Li,Shusen Sun
International Journal of Clinical Pharmacy. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 Knowledge, Attitudes& Practices of Healthcare Professionals in Hospitals towards the Reporting of Adverse Drug Reactions in Saudi Arabia: a Multi-Centre Cross Sectional Study
Thamir M. AlShammari,Mohammed J Almoslem
Saudi Pharmaceutical Journal. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016
Ibrahim A. Oreagba,Kazeem A. Oshikoya,Comfort Ogar,Abiodun O. Adefurin,Ali Ibrahim,Olufunsho Awodele,Yetunde Oni
Pharmacology Research & Perspectives. 2017; 5(2): e00297
[Pubmed]  [Google Scholar] [DOI]
4 A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms
Cheng Leng Chan,Pei San Ang,Shu Chuen Li
Drug Safety. 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Pharmacovigilance activities in ASEAN countries
Wimon Suwankesawong,Teerapon Dhippayom,Wei-Chuen Tan-Koi,Chuenjid Kongkaew
Pharmacoepidemiology and Drug Safety. 2016;
[Pubmed]  [Google Scholar] [DOI]
6 Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation
Gulnihal Ozcan,Emel Aykac,Yelda Kasap,Nergiz T. Nemutlu,Ebru Sen,N. Demet Aydinkarahaliloglu
Drugs - Real World Outcomes. 2016;
[Pubmed]  [Google Scholar] [DOI]
7 An overview of the pharmacovigilance system in India
Niti Mittal,Rakesh Mittal,M. C. Gupta
Clinical Research and Regulatory Affairs. 2016; 33(1): 4
[Pubmed]  [Google Scholar] [DOI]
8 Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis
Edouard Ledent,Alfons Lieftucht,Hubert Buyse,Keiji Sugiyama,Michael Mckenna,Katsiaryna Holl
Drug Safety. 2016; 39(3): 219
[Pubmed]  [Google Scholar] [DOI]
9 Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective
Shashidhar Swamy,Meenakshi Mourya,Ganesh Kadhe,Amey Mane,Sandesh Sawant
Expert Opinion on Drug Safety. 2015; 14(9): 1409
[Pubmed]  [Google Scholar] [DOI]
10 Pharmacy students’ knowledge and perceptions about adverse drug reactions reporting and pharmacovigilance
Kingston Rajiah,Mari Kannan Maharajan,Shashina Nair
Saudi Pharmaceutical Journal. 2015;
[Pubmed]  [Google Scholar] [DOI]
11 Pharmacovigilance in resource-limited countries
Sten Olsson,Shanthi N Pal,Alex Dodoo
Expert Review of Clinical Pharmacology. 2015; 8(4): 449
[Pubmed]  [Google Scholar] [DOI]
12 Post-marketing monitoring of intussusception after rotavirus vaccination in Japan
Vincent Bauchau,Lionel Van Holle,Olivia Mahaux,Katsiaryna Holl,Keiji Sugiyama,Hubert Buyse
Pharmacoepidemiology and Drug Safety. 2015; 24(7): 765
[Pubmed]  [Google Scholar] [DOI]
13 Medication Errors in the Southeast Asian Countries: A Systematic Review
Shahrzad Salmasi,Tahir Mehmood Khan,Yet Hoi Hong,Long Chiau Ming,Tin Wui Wong,Jong-Ling Fuh
PLOS ONE. 2015; 10(9): e0136545
[Pubmed]  [Google Scholar] [DOI]
14 Potential impact of subsequent entry biologics in nephrology practice in Canada
Daniel J Martinusen,Clifford Lo,Judith G Marin,Nicole W Tsao,Marianna Leung
Canadian Journal of Kidney Health and Disease. 2014; 1(1)
[Pubmed]  [Google Scholar] [DOI]


Read this article